Language:
English
In:
Virology, 2007, Vol.362(1), pp.26-37
Description:
Infection with the SARS-associated coronavirus (SARS-CoV) induces an atypical pulmonary disease with a high lethality rate. Although the initial SARS epidemic was contained, sporadic outbreaks of the disease still occur, suggesting a continuous need for a vaccine against this virus. We therefore explored exosome-based vaccines containing the spike S proteins of SARS-CoV. S-containing exosomes were obtained by replacing the transmembrane and cytoplasmic domains of the S protein by those of VSV-G. The immunogenicity and efficacy of the S-containing exosomes were tested in mice and compared to an adenoviral vector vaccine expressing the S protein. Both, S-containing exosomes and the adenoviral vector vaccine induced neutralizing antibody titers. After priming with the SARS-S exosomal vaccine and boosting with the adenoviral vector the neutralizing antibody titers exceeded those observed in the convalescent serum of a SARS patient. Both approaches were effective in a SARS-S-expressing tumor challenge model and thus warrant further investigation.
Keywords:
Sars-Cov ; S Spike ; Vaccine ; Exosome ; Adenoviral Vector ; Biology
ISSN:
0042-6822
E-ISSN:
1096-0341
DOI:
10.1016/j.virol.2006.12.011
URL:
View record in ScienceDirect (Access to full text may be restricted)
URL:
View full text in ScienceDirect
Bookmarklink
